通过EGR1介导的代谢重编程到氧化酸化有助于B细胞淋巴瘤中IBRUTINIB耐药性
Yunxia Liu1,2, Shuichi Kimpara1,2, Nguyet M Hoang1,2
1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Blood
|September 22, 2023
概括
早期生长反应基因1 (EGR1) 通过重编程新陈代谢,驱动淋巴瘤中的易布鲁替尼抗性. 用甲福明或IM156向氧化酸化克服了这种抗性,为复发或耐药B细胞恶性瘤患者提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 代谢重编程 代谢重编程
背景情况:
- 布鲁顿氨酸激酶 (BTK) 抑制剂,如易布鲁替尼,在B细胞恶性瘤中显示出临床成功.
- 获得药物耐药性限制了与ibrutinib治疗的患者的长期存活率.
- 识别耐药性机制对于开发有效疗法至关重要.
研究的目的:
- 研究早期生长反应基因1 (EGR1) 在ibrutinib耐药性中的作用.
- 阐明EGR1介导抗性的分子机制.
- 评估针对EGR1介导抗性的治疗策略.
主要方法:
- 在ibrutinib耐药淋巴瘤细胞中对EGR1表达的分析.
- 对EGR的遗传和药理操作1.1.
- 研究EGR1对细胞代谢的影响,特别是氧化酸化 (OXPHOS).
- 在体外和体内使用甲福明和IM156向OXPHOS的研究.
主要成果:
- EGR1表达在耐易布鲁替尼布的地幔细胞淋巴瘤 (MCL) 和扩散的大B细胞淋巴瘤 (DLBCL) 细胞中升高,并进一步由易布鲁替尼布上调.
- 过度表达的EGR1通过TCF4.4的自我调节来调解ibrutinib的耐药性.
- 通过激活PDP1,EGR1诱导了对OXPHOS的代谢重编程,增加了ATP生产和淋巴瘤细胞存活率.
- 甲福明和IM156在体外和患者衍生的异种移植模型中抑制了耐易布鲁丁尼布淋巴瘤细胞的生长.
结论:
- EGR1是MCL和DLBCL中ibrutinib耐药性的关键调解者.
- 对OXPHOS的EGR1驱动的代谢重编程是抵抗的一个关键机制.
- 用甲胺或IM156向OXPHOS是一种有前途的治疗策略,用于克服复发性/耐药B细胞恶性瘤中对ibrutinib的耐药性.
相关概念视频
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
B Cell Activation and Differentiation
1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K


